Rulixitinib and thalidomide for myelofibrosis – pro
reliminary resutls of a pahse II showed that: “has demonstrated a promising efficacy signal in this initial analysis of an ongoing phase II study, and appears to be well tolerated. Platelet count increases were observed in all patients who entered study with baseline thrombocytopenia, a response which appears to be maintained in the majority of patients observed 6 months after starting combination therapy. As well, anemia responses were observed in 3 of 5 evaluable patients. Collectively, these data indicate a potential role for this regimen in patients with anemia and/or thrombocytopenia, who otherwise have limited treatment options. “.
Raajit K. Rampal, MD PhD , Srdan Verstovsek, MD PhD , Sean M Devlin, PhD , Eytan M. Stein, MD , Tapan M. Kadia, MD , Michael J. Mauro, MD , Naveen Pemmaraju, MD , Kelsey Alvarez, RN , Nicole Ard , Tawni Goodman , Kelly Marek , Prithviraj Bose, MD, Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study. Blood Volume 132, Issue Supplement 1
November 29 2018